Abstract
Blonanserin is an atypical antipsychotic drug with dopamine D2, D3 and serotonin 5-HT2A receptor antagonism. We jointly developed the world’s first antipsychotic transdermal patch containing blonanserin as active pharmaceutical ingredient with Nitto Denko Corporation, and started domestic sales in September 2019. There are three technical hurdles in formulation development of transdermal patch： skin permeability, skin irritation, and adhesiveness. We overcame these technical hurdles and succeeded in developing the formulation of LONASENⓇ Tape. Here, along with detail report on the formulation development, the background to development and the results of clinical studies are also described.
